Trial Profile

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Phytomenadione; Phytomenadione
Indications Carcinoma; Liver cancer
Focus Therapeutic Use

Most Recent Events

25 Oct 2019 Status changed from active, no longer recruiting to completed.
17 Apr 2016 Primary endpoint has been met; (Overall Survival), according to the results published.
17 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com